OSRH

OSR Health, Inc. (OSRH) | Rumor.io

OSR Health

OSRH

Attention (50-day avg)0.01%

Attention rank (50-day avg)#471

Bullish sentiment (50-day avg)84%

Price to earnings ratio10.5

Market capitalization7.2M

Earnings per share-0.3

Dividend yield (TTM)—

Revenue (annual)2.9M

Net income (annual)-27.1M

Social

What share of all stock conversation is about OSRH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% -0.01	0% +0

Sep 24

$OSRH is scheduled to attend a Nasdaq Hearings Panel compliance meeting/hearing, where the company will submit its plan of compliance, which will be reviewed by both the Panel and Nasdaq Listing Qualifications Staff before the hearing.
The company has added approximately 4,000 more shares in the morning, and the spread is 20%.
There is anticipation that the company's stock price may move up before receiving uplist news, potentially due to a leak, and then move back down after the news is received.

Generated by AI

Sentiment

Of the messages about OSRH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	75% -17.5	89.46% +5.52	88.37% -1.27
Bearish	50% new	25% +17.5	10.54% -5.52	11.63% +1.27

Bullish· Sep 2

The company has received $15 million in funding at $10 per share, which is a 29.63 times premium from the current market price.
The entire float of 16.6 million shares can be purchased for just $5.6 million, making it an attractive investment opportunity.
The company's market capitalization of $11.85 million is grossly undervalued, and even at $1, the market cap would be $35 million, with upcoming catalysts and a significant increase in value expected.

Bearish· Aug 19

The stock price has been distressed due to alleged market manipulation, with some users suggesting that naked short selling has been used to drive down the price.
The company's credibility has been severely damaged due to a lack of news and a poor target price, with some users expressing doubt about the company's ability to produce anything of value.
The stock's volatility has been intense, with some users suggesting that it has been caused by the company's stop loss orders and the aggressive averaging down by investors.

Generated by AI

Topics

Of the messages about OSRH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	60.53%	6.93%
Technical Analysis	—	—	39.47%	4.69%
Controversies	—	—	0%	0.06%
Analysts	—	—	0%	44.54%
Earnings	—	—	0%	0%
Macro	—	—	0%	43.78%

Announcements· May 7

The company has signed a definitive global licensing agreement for VXM01, a Phase 3-ready oral DNA immunotherapy platform, with up to $815M in milestone payments and royalties.
The licensing deal has improved shareholder value capture, with milestone payments and royalties flowing directly to the parent company, and BCME has agreed to potential $15M equity participation at $10/share.
The company has also signed an NDA with Sinopharm, China's largest pharmaceutical company, for a glucose monitoring technology, and has seen strong partnership momentum in Woori IO, with discussions with pharma companies underway.

Technical Analysis· Aug 18

$OSRH needs to hold $0.48 structure to remain bullish and a break above $0.80 resistance could lead to a move towards $0.85/0.9+.
The stock is on an uptrend on the intraday chart and a break above $0.80 could send the price over $1.
The stock is forming a cup and handle on the 1M chart and a break above $0.83 resistance is expected to lead to a significant price increase.

Generated by AI

Community

Of the messages about OSRH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	31.03%	63.38%	69.22%	30.82%
Newcomers	68.97%	36.62%	30.78%	69.18%

Regulars· Sep 21

The regulars are waiting for a fair price level of $3-5, with some already selling at lower prices.
The volume of shares being bought and sold is increasing, and some are expecting a move past $1.
There are concerns about the lack of news from the CEO, and some are wondering if Nasdaq will grant a final extension, potentially affecting the share price.

Newcomers· Sep 1

Many newcomers are excited about the potential of OSRH, with some even joking about getting tattoos if the stock reaches $10.
Some are concerned about the stock's low price, with one user predicting a surge in price once it breaks $0.30.
A few users are experiencing mixed emotions about the stock's sudden price increases, with one user expressing relief that the stock is moving in their favor.

Generated by AI

NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report on (NASDAQ:OSRH), a global healthcare holding company advancing oral immunotherapies for cancer and age-related disease, non-invasive glucose monitoring technology, and fourth-party logistics (4PL) operations.This release is being issued as an updated version of EGR's previously published press relea

1mo agoYahoo Finance

OSR Holdings Appeals Nasdaq Delisting After Bid Price Noncompliance

Detailed price information for Osr Health Inc (OSRH) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following ...

1mo agoYahoo Finance

Nasdaq to delist OSR Health after bid price compliance failure

1mo agoInvesting.com

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications ...

1mo agoYahoo Finance

OSR Health faces Nasdaq delisting deadline, cites licensing talks

1mo agoInvesting.com

Also Discussed

Investors talking about OSRH also mention

#	Name	Attention
1	Aspire Biopharma Holdings, Inc.ASBP	0%new
2	Xiao-I Corporation American Depositary SharesAIXI	0.01%+0.01
3	VIVK - Vivakor, Inc.	——
4	Inno Holdings Inc.INHD	0%new
5	Founder Group Ltd. Class A Ordinary SharesFGL	0%0
6	Cycurion Inc.CYCU	0%0
7	SGN - Signing Day Sports, Inc.	——
8	IVP - Inspire Veterinary Partners, Inc.	——
9	Decent Holding Inc. Class A Ordinary SharesDXST	0.02%new
10	Linkers Industries LimitedLNKS	0%0

OSR Health, Inc.

Healthcare
Biotechnology

OSR Health, Inc. is a healthcare holding company focused on developing and supporting a portfolio of biomedical therapies and medical technologies. Through its subsidiaries, the company is active in oral immunotherapies for cancer, design-augmented biologics for degenerative and age-related conditions, neurovascular intervention devices and systems, and non-invasive blood glucose monitoring technologies. It also distributes medical devices and related systems in Korea, giving it a mix of therapeutic development and commercial healthcare operations. Headquartered in Bellevue, Washington, OSR Health operates across the United States, Europe, and Korea, using a hub-and-spoke structure to manage specialized businesses in biotechnology, medtech, and healthcare distribution. The company’s role in the market is centered on advancing clinical-stage and preclinical assets while maintaining a diversified healthcare platform across multiple product categories.

Website

Location

10900 NE 4th Street

Bellevue, WA, 98004

United States

Social

What share of all stock conversation is about OSRH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% -0.01	0% +0

Sep 24

$OSRH is scheduled to attend a Nasdaq Hearings Panel compliance meeting/hearing, where the company will submit its plan of compliance, which will be reviewed by both the Panel and Nasdaq Listing Qualifications Staff before the hearing.
The company has added approximately 4,000 more shares in the morning, and the spread is 20%.
There is anticipation that the company's stock price may move up before receiving uplist news, potentially due to a leak, and then move back down after the news is received.

Generated by AI

Sentiment

Of the messages about OSRH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	75% -17.5	89.46% +5.52	88.37% -1.27
Bearish	50% new	25% +17.5	10.54% -5.52	11.63% +1.27

Bullish· Sep 2

The company has received $15 million in funding at $10 per share, which is a 29.63 times premium from the current market price.
The entire float of 16.6 million shares can be purchased for just $5.6 million, making it an attractive investment opportunity.
The company's market capitalization of $11.85 million is grossly undervalued, and even at $1, the market cap would be $35 million, with upcoming catalysts and a significant increase in value expected.

Bearish· Aug 19

The stock price has been distressed due to alleged market manipulation, with some users suggesting that naked short selling has been used to drive down the price.
The company's credibility has been severely damaged due to a lack of news and a poor target price, with some users expressing doubt about the company's ability to produce anything of value.
The stock's volatility has been intense, with some users suggesting that it has been caused by the company's stop loss orders and the aggressive averaging down by investors.

Generated by AI

Topics

Of the messages about OSRH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	60.53%	6.93%
Technical Analysis	—	—	39.47%	4.69%
Controversies	—	—	0%	0.06%
Analysts	—	—	0%	44.54%
Earnings	—	—	0%	0%
Macro	—	—	0%	43.78%

Announcements· May 7

The company has signed a definitive global licensing agreement for VXM01, a Phase 3-ready oral DNA immunotherapy platform, with up to $815M in milestone payments and royalties.
The licensing deal has improved shareholder value capture, with milestone payments and royalties flowing directly to the parent company, and BCME has agreed to potential $15M equity participation at $10/share.
The company has also signed an NDA with Sinopharm, China's largest pharmaceutical company, for a glucose monitoring technology, and has seen strong partnership momentum in Woori IO, with discussions with pharma companies underway.

Technical Analysis· Aug 18

$OSRH needs to hold $0.48 structure to remain bullish and a break above $0.80 resistance could lead to a move towards $0.85/0.9+.
The stock is on an uptrend on the intraday chart and a break above $0.80 could send the price over $1.
The stock is forming a cup and handle on the 1M chart and a break above $0.83 resistance is expected to lead to a significant price increase.

Generated by AI

Community

Of the messages about OSRH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	31.03%	63.38%	69.22%	30.82%
Newcomers	68.97%	36.62%	30.78%	69.18%

Regulars· Sep 21

The regulars are waiting for a fair price level of $3-5, with some already selling at lower prices.
The volume of shares being bought and sold is increasing, and some are expecting a move past $1.
There are concerns about the lack of news from the CEO, and some are wondering if Nasdaq will grant a final extension, potentially affecting the share price.

Newcomers· Sep 1

Many newcomers are excited about the potential of OSRH, with some even joking about getting tattoos if the stock reaches $10.
Some are concerned about the stock's low price, with one user predicting a surge in price once it breaks $0.30.
A few users are experiencing mixed emotions about the stock's sudden price increases, with one user expressing relief that the stock is moving in their favor.

Generated by AI

OSR Health

Social

Sep 24

Bullish· Sep 2

Bearish· Aug 19

Announcements· May 7

Technical Analysis· Aug 18

Regulars· Sep 21

Newcomers· Sep 1

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.

OSR Holdings Appeals Nasdaq Delisting After Bid Price Noncompliance

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

Nasdaq to delist OSR Health after bid price compliance failure

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

OSR Health faces Nasdaq delisting deadline, cites licensing talks

Also Discussed

OSR Health, Inc.

Company Information

Location

Social

Sep 24

Bullish· Sep 2

Bearish· Aug 19

Announcements· May 7

Technical Analysis· Aug 18

Regulars· Sep 21

Newcomers· Sep 1

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.

OSR Holdings Appeals Nasdaq Delisting After Bid Price Noncompliance

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

Nasdaq to delist OSR Health after bid price compliance failure

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

OSR Health faces Nasdaq delisting deadline, cites licensing talks

Also Discussed